Analyst consensus rating
Radiopharm Theranostics Analyst Rating: none
RADX is rated none by 6 analysts with a $17.50 target. As of 2026-08-23.
Direct answer
Radiopharm Theranostics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.50.
Forecast evidence checked August 23, 2026.
Get free Radiopharm Theranostics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.44
- Average price target
- $17.50
- High price target
- $30.92
- Low price target
- $12.82
- Low target gap
- +425.2%
- Target upside
- +617.1%
- High target gap
- +1,167.1%
- Target range width
- 741.8%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Radiopharm Theranostics?
Radiopharm Theranostics has a verified none consensus. The same dataset has an average price target of $17.50.
How far are Radiopharm Theranostics's low and high targets from the recorded price?
The low target implies +425.2%, while the high target implies +1,167.1%.
How many analysts are included in Radiopharm Theranostics's consensus?
The verified consensus includes 6 analysts.
How is Radiopharm Theranostics's target upside or downside calculated?
The average target of $17.50 is divided by the recorded price of $2.44, then one is subtracted to produce +617.1%. This does not guarantee a future return.
When was Radiopharm Theranostics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.